Top

Published in:

01-12-2018 | Commentary

Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents

Authors: Charles W. Given, Barbara A. Given, Alla Sikorskii, John C. Krauss, Eric Vachon

Published in: Supportive Care in Cancer | Issue 12/2018

Abstract

Conducting research into supportive care for patients as they initiate treatment with oral oncolytic agents poses numerous new challenges. Some of these medications have very complex dosing schedules and produce symptoms that patients need to manage at home with less reliance on oncology clinicians. We describe lessons learned from a multi-site trial designed to improve adherence to these medications and self-management of symptoms among patients newly prescribed oral oncolytic agents. Identifying these challenges can assist researchers to improve the integrity of their future supportive care trials.

Middendorff G, Elsey R, Lounsbery B, Chadwell R (2017) Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents. J Oncol Pharm Pract 24:371–378. https://doi.org/10.1177/1078155217708022 CrossRefPubMed

Siddiqi AE, Sikorskii A, Given CW, Given B (2008) Early participant attrition from clinical trials: role of trial design and logistics. Clin Trials 5(4):328–335. https://doi.org/10.1177/1740774508094406 CrossRefPubMedPubMedCentral

Atkinson TM, Rodríguez VM, Gordon M, Avildsen I, Emanu J, Jewell S, Anselmi K, Ginex P (2016) The association between patient-reported and objective oral anticancer medication adherence measures: a systematic review. Oncol Nurs Forum 43(5):576–582. https://doi.org/10.1188/16.ONF.576-582 CrossRefPubMedPubMedCentral

Bergsbaken JJ, Eickhoff JC, Buss BA, Mably MS, Kolesar JM (2016) Assessment of adherence with oral anticancer agents in oncology clinical trials: a systematic review. J Oncol Pharm Pract 22(1):105–113. https://doi.org/10.1177/1078155214567163 CrossRefPubMed

Gebbia V, Bellavia M, Banna GL, Russo P, Ferraù F, Tralongo P, Borsellino N (2013) Treatment monitoring program for implementation of adherence to second-line erlotinibe for advanced non-small cell lung cancer. Clin Lung Cancer 14(4):390–398. https://doi.org/10.1016/j.cllc.2012.11.007 CrossRefPubMed

Timmers L, Boons CC, Kropff F et al (2014) Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol 53(2):259–267. https://doi.org/10.3109/0284186X.2013.844353 CrossRefPubMed

Goldstein DA, Gordon N, Davidescu M et al (2017) A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer. J Natl Cancer Inst 109(11):djx063. https://doi.org/10.1093/jnci/djx063 CrossRef

Huang WC, Chen CY, Lin SJ, Chang CS (2016) Medication adherence to oral anticancer drugs: systematic review. Expert Rev Anticancer Ther 16(4):423–432. https://doi.org/10.1586/14737140.2016.1159515 CrossRefPubMed

Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E, Tarquinio C (2014) Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 23(1):22–35. https://doi.org/10.1111/ecc.12124 CrossRef

10.

Okumura LM (2018) How to report adherence to treatment as clinically relevant data-making a case of CML and TKI. Support Care Cancer 26(2):323–324. https://doi.org/10.1007/s00520-017-3809-2 CrossRefPubMed

11.

Fishbein JN, Nisotel LE, MacDonald JJ et al (2017) Mobile application to promote adherence to oral chemotherapy and symptom management: a protocol for design and development. JMIR Res Protoc 6(4):e62. https://doi.org/10.2196/resprot.6198 CrossRefPubMedPubMedCentral

12.

Pereira-Salgado A, Westwood JA, Russell L, Ugalde A, Ortlepp B, Seymour JF, Butow P, Cavedon L, Ong K, Aranda S, Breen S, Kirsa S, Dunlevie A, Schofield P (2017) Mobile health intervention to increase oral cancer therapy adherence in patients with chronic myeloid leukemia (the REMIND system): clinical feasibility and acceptability assessment. JMIR Mhealth Uhealth 5(12):e184. https://doi.org/10.2196/mhealth.8349 CrossRefPubMedPubMedCentral

13.

Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):54–76. https://doi.org/10.1634/theoncologist.2015-0405 CrossRef

14.

Zerillo JA, Goldenberg BA, Kotecha RR, Tewari AK, Jacobson JO, Krzyzanowska MK (2018) Interventions to improve oral chemotherapy safety and quality: a systematic review. JAMA Oncol 1 4(1):105–117. https://doi.org/10.1001/jamaoncol.2017.0625 CrossRef

15.

McCall C, Maynes B, Zou CC, Zhang NJ (2010) RMAIS: RFID-based medication adherence intelligence system 2010:3768–3771. doi: https://doi.org/10.1109/IEMBS.2010.5627529

16.

Spahni S, Lovis C, Ackermann M, Mach N, Bonnabry P, Geissbuhler A (2006) Guarantying the quality of chemotherapy: from the order to the administration. Stud Health Technol Inform 124:241–246PubMed

17.

Safdari R, Maserat E, Maserat E (2012) RFID technology in health environment opportunities and challenges for modern cancer care. Asian Pac J Cancer Prev 13(12):6533–6537CrossRef

18.

Bach PB, Saltz LB (2017) Raising the dose and raising the cost the case of pembrolizumab in lung cancer. J Natl Cancer Inst 109(11):djx125. https://doi.org/10.1093/jnci/djx125 CrossRef

19.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26:1547–1573. https://doi.org/10.1093/annonc/mdv249 CrossRefPubMed

20.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL (2016) Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34(24):2925–2934. https://doi.org/10.1200/JCO.2016.68.2518 CrossRefPubMed

Title: Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents
Authors: Charles W. Given
Barbara A. Given
Alla Sikorskii
John C. Krauss
Eric Vachon
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 12/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4414-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2018

Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution

New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study

Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment

Are healthcare professionals being left in the lurch? The role of structural barriers and information resources to promote physical activity to cancer patients

Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction

Reflections on the implementation of screening for distress (sixth vital sign) in Canada: key lessons learned

Keynote webinar | Spotlight on antibody–drug conjugates in cancer